alari remedi effort focu balanc led
signific cut top-line cc growth guidanc given
lower top-line growth profil uncertainti recoveri path would
move sidelin downgrad market perform
downgrad given lower top-line trajectori uncertainti recoveri path
management recent publicli reveal alari shipment return full
announc today continu discuss fda alari system
softwar remedi plan requir addit file previous anticip
result lost sale plan submit comprehens regulatori fill
resolut major focu balanc result
would move sidelin given uncertainti around recoveri path get
back higher top-line revenu growth clip given uncertainti alari remedi
potenti trickl uncertainti coronaviru impact
busi hit expect volume-bas procur process china
provinc new hit peripher cath continu impact
headwind neg dcb impact expect revis
top-line guidanc rang low end med-tech coverag univers
compar market perform lower hsd top-line rang
sever outperform name downgrad market perform revis pt
ep in-lin peer median multipl
alari remedi effort focu qualiti system team initi
thought could use phase approach made alari softwar updat releas
time chang made requir new clearanc releas
recent alari softwar updat dec resum shipment howev management
learn week fda disagre conclus histor releas
requir clearanc request softwar enhanc recal
remedi updat batch singl comprehens file extend
time remedi requir go back resolv process time
lead meaning guidanc takedown factor addit alari regulatori
file compani lower cc growth guidanc vs prior
reflect impact expect sale loss alari bd medic segment guid flat vs
coronaviru dynam also factor lower guidanc addit md
headwind face china compani deal impact relat
coronaviru region facil offic china although
citi provinc epicent outbreak roughli product
manufactur facil use sold within countri remain
product export believ suffici inventori meet
current demand compani acknowledg dynam situat
difficult predict observ fewer peopl go hospit seek care
consist messag heard compani
anticip creat headwind approxim quarter
remind sale china repres roughli sale
pleas see page report import disclosur
appear posit gener low-singl digit top-lin growth ep growth
headwind fy includ alari pump remedi coronaviru
neg dcb impact china md price impact partli off-set solid
execut unaffect busi segment upsid oper target via on-going
stand-alone improv contribut carefus bard rate share
fda file alari remedi expect
headwind alari pump
remedi coronaviru china
upsid rel formal accretion/
price pressur like continu
volum pressur like intensifi
solid execut rel expect
headwind abat sooner expect
carefusion/bard synergi accret
target conserv
strong growth emerg market
headwind intensifi time extend
bd guidanc prove high
bard miss accret synergi
concern strategi
becton dickinson compani bd global medic technolog compani engag
develop manufactur sale medic devic instrument system
reagent use healthcar institut life scienc research clinic laboratori
pharmaceut industri gener public
segment perform headwind includ china impact md alari impact
partli off-set life intervent result
take look segment medic sale short street
estim compris constant currenc declin indic
perform medic impact new volume-bas procur process
adopt certain chines provinc specif cathet busi within
medic deliveri solut portfolio china medic deliveri solut sale growth
total constant currenc basi help strength vascular
care outsid china medic manag solut within medic sale declin
constant currenc basi due limit instal alari pump
dynam compani expect independ ad regulatori requir
alari disclos thursday life scienc experienc growth
constant currenc basi quarter total revenu quarter
well ahead street expect driven bioscienc better
street flu season intervent deliv revenu
ahead consensu cc growth solid pi perform dcb
headwind impact slightli better expect anniversari
lower-than-anticip op margin vs model gross margin came
ahead estim street forecast repres
year-over-year improv bp perform gain off-set impact
currenc oper margin bp prior-year
period compani bp expens leverag off-set bp defer comp
expens bp currenc net contract result
project well street consensu rel
estim bdx lower net interest/oth expens vs tax expens
vs compens margin differ yield ep
guidanc point consid
sale peripher cathet busi given volum base procur
china management previous taken expect taken
addit due acceler provinc tender led distributor
take inventori anticip tender leav roughli
busi go forward gm guidanc came
sg guidanc went look oper margin
made slight cut prior guidanc expect bp expans rang
prior impli expans roughli bp
ep rang also lower repres earn growth
currenc neutral basi prior rang
bdx revenu came vs street expect impli
constant currenc growth top-line result slightli ahead management guidanc
rang growth impli q/q deceler publicli
relay china md tender impact reportedli de minimu
influenza season provid tailwind ep match estim
top end manag guidanc rang result better
consensu forecast
compani report thomson eikon cowen compani
chg medic deliveri solut manag solut system life system system intervent critic chang good gross gross net interest expens expens incom incom tax incom oper ex-intang share estim cowen
compani report thomson eikon cowen compani
mm except per share organ gener oper non-oper interest earn per cowen
cowen compani
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
competit dynam global potenti regulatori delay potenti delay
time product launch emerg develop market econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend share repurchas fluctuat foreign exchang rate
downsid risk includ limit fail execut integr
effort includ hit synergi target engag value-destroy activ
experienc delay product develop regulatori approv face
reduct reimburs price pressur key product incur patent
infring and/or product liabil lawsuit lose market share price power
due competit fail deliv oper goal guidanc face
regulatori remedi process come experienc macroeconom
deterior impact end market custom
upsid risk includ limit time sever regulatori
remedi better expect macroeconom environ improv sooner
meaning expect busi perform execut exce expect
potenti price pressur abat sooner meaning expect
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
